Coronary stents in patients with ST-elevation myocardial infarction and chronic kidney disease undergoing primary percutaneous coronary intervention

Khurshid Ahmed, Myung Ho Jeong, Rabin Chakraborty, Sumera Ahmed, Young Joon Hong, Doo Sun Sim, Keun Ho Park, Ju Han Kim, Youngkeun Ahn, Jung Chaee Kang, Myeong Chan Cho, Chong Jin Kim, Young Jo Kim, Shung Chull Chae, Jong Hyun Kim, Seung Ho Hur, In Whan Seong, Donghoon Choi, Jei Keon Chae, Taek Jong HongJae Young Rhew, Doo Il Kim, In Ho Chae, Junghan Yoon, Bon Kwon Koo, Byung Ok Kim, Myoung Yong Lee, Kee Sik Kim, Jin Young Hwang, Seok Kyu Oh, Nae Hee Lee, Kyoung Tae Jeong, Seung Jea Tahk, Jang Ho Bae, Seung Woon Rha, Keum Soo Park, Kyoo Rok Han, Tae Hoon Ahn, Moo Hyun Kim, Ki Bae Seung, Wook Sung Chung, Ju Young Yang, Chong Yun Rhim, Hyeon Cheol Gwon, Seong Wook Park, Young Youp Koh, Seung Jae Joo, Soo Joong Kim, Dong Kyu Jin, Jin Man Cho, Sang Wook Kim, Jeong Kyung Kim, Tae Ik Kim, Deug Young Nah, Si Hoon Park, Sang Hyun Lee, Seung Uk Lee, Hang Jae Chung, Jang Hyun Cho, Seung Won Jin, Yangsoo Jang, Jeong Gwan Cho, Seung Jung Park

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background and Objectives: Chronic kidney disease (CKD) is associated with poor outcomes after percutaneous coronary intervention (PCI). We sought to compare different coronary stents used during primary PCI in patients with ST-elevation myocardial infarction (STEMI) and CKD. Subjects and Methods: We selected 2408 consecutive STEMI patients with CKD (estimated glomerular filtration rate <60 mL/min/1.73 m2) undergoing primary PCI and divided them into 5 groups based on the type of stent implanted: 1) bare metal stent (BMS), 2) paclitaxel-eluting stent (PES), 3) sirolimus-eluting stent (SES), 4) zotarolimus-eluting stent (ZES), or 5) everolimus-eluting stent (EES). The study end-point was the number of major adverse cardiac events (MACE) at 12 months. Results: There was no significant difference in the incidence of 12-month myocardial infarction, target lesion revascularization, or target vessel revascularization between stent groups; however, the overall rate of repeat revascularization differed significantly between groups. All-cause death differed significantly among the groups. The incidence of 12-month MACE in BMS, PES, SES, ZES, and EES was 8.3%, 9.8%, 8.6%, 5.5%, and 2.6%, respectively (p<0.001). Kaplan-Meier analysis did not show a significant differences in 12-month MACE-free survival among the groups (log-rank p=0.076). This finding remained the same after adjusting for multiple confounders (p=0.147). Conclusion: Any of the 5 stents can be used to treat STEMI patients with CKD undergoing primary PCI; all have similar risk of 12-month MACE. This result is hypothesis-generating and warrants further evaluation with a long-term randomized study.

Original languageEnglish
Pages (from-to)830-838
Number of pages9
JournalKorean Circulation Journal
Volume42
Issue number12
DOIs
Publication statusPublished - 2012 Dec 1

Fingerprint

Percutaneous Coronary Intervention
Chronic Renal Insufficiency
Stents
Sirolimus
Paclitaxel
ST Elevation Myocardial Infarction
Metals
Incidence
Kaplan-Meier Estimate
Glomerular Filtration Rate
Disease-Free Survival
Cause of Death
Myocardial Infarction

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Ahmed, Khurshid ; Jeong, Myung Ho ; Chakraborty, Rabin ; Ahmed, Sumera ; Hong, Young Joon ; Sim, Doo Sun ; Park, Keun Ho ; Kim, Ju Han ; Ahn, Youngkeun ; Kang, Jung Chaee ; Cho, Myeong Chan ; Kim, Chong Jin ; Kim, Young Jo ; Chae, Shung Chull ; Kim, Jong Hyun ; Hur, Seung Ho ; Seong, In Whan ; Choi, Donghoon ; Chae, Jei Keon ; Hong, Taek Jong ; Rhew, Jae Young ; Kim, Doo Il ; Chae, In Ho ; Yoon, Junghan ; Koo, Bon Kwon ; Kim, Byung Ok ; Lee, Myoung Yong ; Kim, Kee Sik ; Hwang, Jin Young ; Oh, Seok Kyu ; Lee, Nae Hee ; Jeong, Kyoung Tae ; Tahk, Seung Jea ; Bae, Jang Ho ; Rha, Seung Woon ; Park, Keum Soo ; Han, Kyoo Rok ; Ahn, Tae Hoon ; Kim, Moo Hyun ; Seung, Ki Bae ; Chung, Wook Sung ; Yang, Ju Young ; Rhim, Chong Yun ; Gwon, Hyeon Cheol ; Park, Seong Wook ; Koh, Young Youp ; Joo, Seung Jae ; Kim, Soo Joong ; Jin, Dong Kyu ; Cho, Jin Man ; Kim, Sang Wook ; Kim, Jeong Kyung ; Kim, Tae Ik ; Nah, Deug Young ; Park, Si Hoon ; Lee, Sang Hyun ; Lee, Seung Uk ; Chung, Hang Jae ; Cho, Jang Hyun ; Jin, Seung Won ; Jang, Yangsoo ; Cho, Jeong Gwan ; Park, Seung Jung. / Coronary stents in patients with ST-elevation myocardial infarction and chronic kidney disease undergoing primary percutaneous coronary intervention. In: Korean Circulation Journal. 2012 ; Vol. 42, No. 12. pp. 830-838.
@article{d5e3be1288834764a01f8d7523255733,
title = "Coronary stents in patients with ST-elevation myocardial infarction and chronic kidney disease undergoing primary percutaneous coronary intervention",
abstract = "Background and Objectives: Chronic kidney disease (CKD) is associated with poor outcomes after percutaneous coronary intervention (PCI). We sought to compare different coronary stents used during primary PCI in patients with ST-elevation myocardial infarction (STEMI) and CKD. Subjects and Methods: We selected 2408 consecutive STEMI patients with CKD (estimated glomerular filtration rate <60 mL/min/1.73 m2) undergoing primary PCI and divided them into 5 groups based on the type of stent implanted: 1) bare metal stent (BMS), 2) paclitaxel-eluting stent (PES), 3) sirolimus-eluting stent (SES), 4) zotarolimus-eluting stent (ZES), or 5) everolimus-eluting stent (EES). The study end-point was the number of major adverse cardiac events (MACE) at 12 months. Results: There was no significant difference in the incidence of 12-month myocardial infarction, target lesion revascularization, or target vessel revascularization between stent groups; however, the overall rate of repeat revascularization differed significantly between groups. All-cause death differed significantly among the groups. The incidence of 12-month MACE in BMS, PES, SES, ZES, and EES was 8.3{\%}, 9.8{\%}, 8.6{\%}, 5.5{\%}, and 2.6{\%}, respectively (p<0.001). Kaplan-Meier analysis did not show a significant differences in 12-month MACE-free survival among the groups (log-rank p=0.076). This finding remained the same after adjusting for multiple confounders (p=0.147). Conclusion: Any of the 5 stents can be used to treat STEMI patients with CKD undergoing primary PCI; all have similar risk of 12-month MACE. This result is hypothesis-generating and warrants further evaluation with a long-term randomized study.",
author = "Khurshid Ahmed and Jeong, {Myung Ho} and Rabin Chakraborty and Sumera Ahmed and Hong, {Young Joon} and Sim, {Doo Sun} and Park, {Keun Ho} and Kim, {Ju Han} and Youngkeun Ahn and Kang, {Jung Chaee} and Cho, {Myeong Chan} and Kim, {Chong Jin} and Kim, {Young Jo} and Chae, {Shung Chull} and Kim, {Jong Hyun} and Hur, {Seung Ho} and Seong, {In Whan} and Donghoon Choi and Chae, {Jei Keon} and Hong, {Taek Jong} and Rhew, {Jae Young} and Kim, {Doo Il} and Chae, {In Ho} and Junghan Yoon and Koo, {Bon Kwon} and Kim, {Byung Ok} and Lee, {Myoung Yong} and Kim, {Kee Sik} and Hwang, {Jin Young} and Oh, {Seok Kyu} and Lee, {Nae Hee} and Jeong, {Kyoung Tae} and Tahk, {Seung Jea} and Bae, {Jang Ho} and Rha, {Seung Woon} and Park, {Keum Soo} and Han, {Kyoo Rok} and Ahn, {Tae Hoon} and Kim, {Moo Hyun} and Seung, {Ki Bae} and Chung, {Wook Sung} and Yang, {Ju Young} and Rhim, {Chong Yun} and Gwon, {Hyeon Cheol} and Park, {Seong Wook} and Koh, {Young Youp} and Joo, {Seung Jae} and Kim, {Soo Joong} and Jin, {Dong Kyu} and Cho, {Jin Man} and Kim, {Sang Wook} and Kim, {Jeong Kyung} and Kim, {Tae Ik} and Nah, {Deug Young} and Park, {Si Hoon} and Lee, {Sang Hyun} and Lee, {Seung Uk} and Chung, {Hang Jae} and Cho, {Jang Hyun} and Jin, {Seung Won} and Yangsoo Jang and Cho, {Jeong Gwan} and Park, {Seung Jung}",
year = "2012",
month = "12",
day = "1",
doi = "10.4070/kcj.2012.42.12.830",
language = "English",
volume = "42",
pages = "830--838",
journal = "Korean Circulation Journal",
issn = "1738-5520",
publisher = "Korean Society of Circulation",
number = "12",

}

Ahmed, K, Jeong, MH, Chakraborty, R, Ahmed, S, Hong, YJ, Sim, DS, Park, KH, Kim, JH, Ahn, Y, Kang, JC, Cho, MC, Kim, CJ, Kim, YJ, Chae, SC, Kim, JH, Hur, SH, Seong, IW, Choi, D, Chae, JK, Hong, TJ, Rhew, JY, Kim, DI, Chae, IH, Yoon, J, Koo, BK, Kim, BO, Lee, MY, Kim, KS, Hwang, JY, Oh, SK, Lee, NH, Jeong, KT, Tahk, SJ, Bae, JH, Rha, SW, Park, KS, Han, KR, Ahn, TH, Kim, MH, Seung, KB, Chung, WS, Yang, JY, Rhim, CY, Gwon, HC, Park, SW, Koh, YY, Joo, SJ, Kim, SJ, Jin, DK, Cho, JM, Kim, SW, Kim, JK, Kim, TI, Nah, DY, Park, SH, Lee, SH, Lee, SU, Chung, HJ, Cho, JH, Jin, SW, Jang, Y, Cho, JG & Park, SJ 2012, 'Coronary stents in patients with ST-elevation myocardial infarction and chronic kidney disease undergoing primary percutaneous coronary intervention', Korean Circulation Journal, vol. 42, no. 12, pp. 830-838. https://doi.org/10.4070/kcj.2012.42.12.830

Coronary stents in patients with ST-elevation myocardial infarction and chronic kidney disease undergoing primary percutaneous coronary intervention. / Ahmed, Khurshid; Jeong, Myung Ho; Chakraborty, Rabin; Ahmed, Sumera; Hong, Young Joon; Sim, Doo Sun; Park, Keun Ho; Kim, Ju Han; Ahn, Youngkeun; Kang, Jung Chaee; Cho, Myeong Chan; Kim, Chong Jin; Kim, Young Jo; Chae, Shung Chull; Kim, Jong Hyun; Hur, Seung Ho; Seong, In Whan; Choi, Donghoon; Chae, Jei Keon; Hong, Taek Jong; Rhew, Jae Young; Kim, Doo Il; Chae, In Ho; Yoon, Junghan; Koo, Bon Kwon; Kim, Byung Ok; Lee, Myoung Yong; Kim, Kee Sik; Hwang, Jin Young; Oh, Seok Kyu; Lee, Nae Hee; Jeong, Kyoung Tae; Tahk, Seung Jea; Bae, Jang Ho; Rha, Seung Woon; Park, Keum Soo; Han, Kyoo Rok; Ahn, Tae Hoon; Kim, Moo Hyun; Seung, Ki Bae; Chung, Wook Sung; Yang, Ju Young; Rhim, Chong Yun; Gwon, Hyeon Cheol; Park, Seong Wook; Koh, Young Youp; Joo, Seung Jae; Kim, Soo Joong; Jin, Dong Kyu; Cho, Jin Man; Kim, Sang Wook; Kim, Jeong Kyung; Kim, Tae Ik; Nah, Deug Young; Park, Si Hoon; Lee, Sang Hyun; Lee, Seung Uk; Chung, Hang Jae; Cho, Jang Hyun; Jin, Seung Won; Jang, Yangsoo; Cho, Jeong Gwan; Park, Seung Jung.

In: Korean Circulation Journal, Vol. 42, No. 12, 01.12.2012, p. 830-838.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Coronary stents in patients with ST-elevation myocardial infarction and chronic kidney disease undergoing primary percutaneous coronary intervention

AU - Ahmed, Khurshid

AU - Jeong, Myung Ho

AU - Chakraborty, Rabin

AU - Ahmed, Sumera

AU - Hong, Young Joon

AU - Sim, Doo Sun

AU - Park, Keun Ho

AU - Kim, Ju Han

AU - Ahn, Youngkeun

AU - Kang, Jung Chaee

AU - Cho, Myeong Chan

AU - Kim, Chong Jin

AU - Kim, Young Jo

AU - Chae, Shung Chull

AU - Kim, Jong Hyun

AU - Hur, Seung Ho

AU - Seong, In Whan

AU - Choi, Donghoon

AU - Chae, Jei Keon

AU - Hong, Taek Jong

AU - Rhew, Jae Young

AU - Kim, Doo Il

AU - Chae, In Ho

AU - Yoon, Junghan

AU - Koo, Bon Kwon

AU - Kim, Byung Ok

AU - Lee, Myoung Yong

AU - Kim, Kee Sik

AU - Hwang, Jin Young

AU - Oh, Seok Kyu

AU - Lee, Nae Hee

AU - Jeong, Kyoung Tae

AU - Tahk, Seung Jea

AU - Bae, Jang Ho

AU - Rha, Seung Woon

AU - Park, Keum Soo

AU - Han, Kyoo Rok

AU - Ahn, Tae Hoon

AU - Kim, Moo Hyun

AU - Seung, Ki Bae

AU - Chung, Wook Sung

AU - Yang, Ju Young

AU - Rhim, Chong Yun

AU - Gwon, Hyeon Cheol

AU - Park, Seong Wook

AU - Koh, Young Youp

AU - Joo, Seung Jae

AU - Kim, Soo Joong

AU - Jin, Dong Kyu

AU - Cho, Jin Man

AU - Kim, Sang Wook

AU - Kim, Jeong Kyung

AU - Kim, Tae Ik

AU - Nah, Deug Young

AU - Park, Si Hoon

AU - Lee, Sang Hyun

AU - Lee, Seung Uk

AU - Chung, Hang Jae

AU - Cho, Jang Hyun

AU - Jin, Seung Won

AU - Jang, Yangsoo

AU - Cho, Jeong Gwan

AU - Park, Seung Jung

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Background and Objectives: Chronic kidney disease (CKD) is associated with poor outcomes after percutaneous coronary intervention (PCI). We sought to compare different coronary stents used during primary PCI in patients with ST-elevation myocardial infarction (STEMI) and CKD. Subjects and Methods: We selected 2408 consecutive STEMI patients with CKD (estimated glomerular filtration rate <60 mL/min/1.73 m2) undergoing primary PCI and divided them into 5 groups based on the type of stent implanted: 1) bare metal stent (BMS), 2) paclitaxel-eluting stent (PES), 3) sirolimus-eluting stent (SES), 4) zotarolimus-eluting stent (ZES), or 5) everolimus-eluting stent (EES). The study end-point was the number of major adverse cardiac events (MACE) at 12 months. Results: There was no significant difference in the incidence of 12-month myocardial infarction, target lesion revascularization, or target vessel revascularization between stent groups; however, the overall rate of repeat revascularization differed significantly between groups. All-cause death differed significantly among the groups. The incidence of 12-month MACE in BMS, PES, SES, ZES, and EES was 8.3%, 9.8%, 8.6%, 5.5%, and 2.6%, respectively (p<0.001). Kaplan-Meier analysis did not show a significant differences in 12-month MACE-free survival among the groups (log-rank p=0.076). This finding remained the same after adjusting for multiple confounders (p=0.147). Conclusion: Any of the 5 stents can be used to treat STEMI patients with CKD undergoing primary PCI; all have similar risk of 12-month MACE. This result is hypothesis-generating and warrants further evaluation with a long-term randomized study.

AB - Background and Objectives: Chronic kidney disease (CKD) is associated with poor outcomes after percutaneous coronary intervention (PCI). We sought to compare different coronary stents used during primary PCI in patients with ST-elevation myocardial infarction (STEMI) and CKD. Subjects and Methods: We selected 2408 consecutive STEMI patients with CKD (estimated glomerular filtration rate <60 mL/min/1.73 m2) undergoing primary PCI and divided them into 5 groups based on the type of stent implanted: 1) bare metal stent (BMS), 2) paclitaxel-eluting stent (PES), 3) sirolimus-eluting stent (SES), 4) zotarolimus-eluting stent (ZES), or 5) everolimus-eluting stent (EES). The study end-point was the number of major adverse cardiac events (MACE) at 12 months. Results: There was no significant difference in the incidence of 12-month myocardial infarction, target lesion revascularization, or target vessel revascularization between stent groups; however, the overall rate of repeat revascularization differed significantly between groups. All-cause death differed significantly among the groups. The incidence of 12-month MACE in BMS, PES, SES, ZES, and EES was 8.3%, 9.8%, 8.6%, 5.5%, and 2.6%, respectively (p<0.001). Kaplan-Meier analysis did not show a significant differences in 12-month MACE-free survival among the groups (log-rank p=0.076). This finding remained the same after adjusting for multiple confounders (p=0.147). Conclusion: Any of the 5 stents can be used to treat STEMI patients with CKD undergoing primary PCI; all have similar risk of 12-month MACE. This result is hypothesis-generating and warrants further evaluation with a long-term randomized study.

UR - http://www.scopus.com/inward/record.url?scp=84872706248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872706248&partnerID=8YFLogxK

U2 - 10.4070/kcj.2012.42.12.830

DO - 10.4070/kcj.2012.42.12.830

M3 - Article

C2 - 23323121

AN - SCOPUS:84872706248

VL - 42

SP - 830

EP - 838

JO - Korean Circulation Journal

JF - Korean Circulation Journal

SN - 1738-5520

IS - 12

ER -